Project: Sialylated antigens as immune tolerance inducers: an innovative therapeutic vaccine for MS.

SIAGEN-MS will develop a therapeutic vaccine against Multiple Sclerosis (MS) by modification of myelin-derived peptides through sialylation. The Eurostars project will deliver 1) A sialylated antigen-based therapeutic vaccine that is able to target dendritic cells and/or microglia, 2) in vivo evidence that the therapeutic vaccine is able to slow and inhibit progress of MS, 3) initiated preclinical toxicology and safety assessments.

Acronym SIAGEN-MS (Reference Number: 9059)
Duration 01/01/2015 - 01/01/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 1

Project partner

Number Name Role Country
19340 DC4U B.V. Coordinator Netherlands
19341 Stichting VU-VUmc Partner Netherlands
19342 University of Bern Partner Switzerland
19343 piCHEM Forschungs- und Entwicklungs GmbH Partner Austria
19344 MD Biosciences GmbH Partner Switzerland